Literature DB >> 22966946

Review article: the reversibility of cirrhosis.

A A Sohrabpour1, M Mohamadnejad, R Malekzadeh.   

Abstract

BACKGROUND: Cirrhosis is the end result of many types of chronic liver diseases. Recent developments in the understanding of the process of hepatic fibrogenesis have revealed that the process is a dynamic one and a capacity for recovery from any degree of fibrosis including those associated with cirrhosis is plausible. AIM: To review current evidence of histopathological reversibility following drug therapy of more common aetiologies of cirrhosis.
METHODS: A PubMed search was performed and the evidence for histopathological regression of advanced fibrosis/cirrhosis following drug therapy was reviewed as of the end of February 2012.
RESULTS: There is abundant clinical evidence in support of the idea of the reversibility of cirrhosis in patients with different aetiologies of advanced hepatic disease including viral, autoimmune and metabolic/infiltrative liver disease.
CONCLUSIONS: The concept of cirrhosis has changed from being a form of static and irreversible entity to a dynamic and reversible diseases stage. Novel therapeutic strategies are under investigation to target specific steps in the process of fibrogenesis with the aim of reversing advanced fibrosis/cirrhosis.

Entities:  

Mesh:

Year:  2012        PMID: 22966946     DOI: 10.1111/apt.12044

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  20 in total

1.  Comparison of diffusion-weighted imaging and MR elastography in staging liver fibrosis: a meta-analysis.

Authors:  Weon Jang; Seongil Jo; Ji Soo Song; Hong Pil Hwang; Seong-Hun Kim
Journal:  Abdom Radiol (NY)       Date:  2021-03-26

Review 2.  Comparison of gradient-recalled echo and spin-echo echo-planar imaging MR elastography in staging liver fibrosis: a meta-analysis.

Authors:  Yong Seek Kim; Yu Na Jang; Ji Soo Song
Journal:  Eur Radiol       Date:  2017-11-21       Impact factor: 5.315

3.  Mechanotransduction-modulated fibrotic microniches reveal the contribution of angiogenesis in liver fibrosis.

Authors:  Longwei Liu; Zhifeng You; Hongsheng Yu; Lyu Zhou; Hui Zhao; Xiaojun Yan; Dulei Li; Bingjie Wang; Lu Zhu; Yuzhou Xu; Tie Xia; Yan Shi; Chenyu Huang; Wei Hou; Yanan Du
Journal:  Nat Mater       Date:  2017-11-13       Impact factor: 43.841

4.  MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma.

Authors:  Gábor Lendvai; Tímea Szekerczés; Benedek Gyöngyösi; Krisztina Schlachter; Endre Kontsek; Adrián Pesti; Attila Patonai; Klára Werling; Ilona Kovalszky; Zsuzsa Schaff; András Kiss
Journal:  Pathol Oncol Res       Date:  2018-11-09       Impact factor: 3.201

5.  LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.

Authors:  Ji Soo Song; Eun Jung Choi; Seung Bae Hwang; Hong Pil Hwang; HyeMi Choi
Journal:  Eur Radiol       Date:  2018-06-19       Impact factor: 5.315

6.  Intraportal Infusion of Bone Marrow Mononuclear or CD133+ Cells in Patients With Decompensated Cirrhosis: A Double-Blind Randomized Controlled Trial.

Authors:  Mehdi Mohamadnejad; Massoud Vosough; Shirin Moossavi; Sepideh Nikfam; Soura Mardpour; Shahram Akhlaghpoor; Mandana Ashrafi; Vajiheh Azimian; Neda Jarughi; Seyedeh-Esmat Hosseini; Fatemeh Moeininia; Mohamad Bagheri; Maryam Sharafkhah; Nasser Aghdami; Reza Malekzadeh; Hossein Baharvand
Journal:  Stem Cells Transl Med       Date:  2015-12-10       Impact factor: 6.940

Review 7.  Pathogenesis of liver cirrhosis.

Authors:  Wen-Ce Zhou; Quan-Bao Zhang; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

8.  Autoimmune hepatitis unmasked by nimesulide.

Authors:  Rita Magalhães; Margarida Fonseca; Ilídio Brandão; Sofia Caridade
Journal:  BMJ Case Rep       Date:  2016-01-20

9.  Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.

Authors:  Michele Malaguarnera; Massimo Motta; Marco Vacante; Giulia Malaguarnera; Filippo Caraci; Giuseppe Nunnari; Caterina Gagliano; Carmela Greco; Giuseppe Chisari; Filippo Drago; Gaetano Bertino
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

10.  Resolution of chronic bacterial-induced prostatic inflammation reverses established fibrosis.

Authors:  Letitia Wong; Paul R Hutson; Wade Bushman
Journal:  Prostate       Date:  2014-10-04       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.